Previous 10 | Next 10 |
Collaboration to discover and evaluate novel product concepts based on the combination of Genmab’s antibodies and bispecific antibody technologies with Bolt’s proprietary immune-stimulating antibody conjugate (ISAC) platform Companies intend to develop multiple...
Genmab (GMAB) announces today that EMA's Committee for Medicinal Products for Human Use ((CHMP)) has adopted a positive opinion and recommended granting marketing authorization for Darzalex SC, in combination with bortezomib, cyclophosphamide, and dexamethasone for the treatment of adult pati...
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q1 2021 Earnings Call May 6, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q1 2021 Earnings Call Transcript
Genmab A/S (GMAB) Q1 2021 Earnings Conference Call May 05, 2021 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Wimal Kapadia - Bernstein Michael Schmidt - Guggenheim...
Genmab A/S (GMAB): Q1 GAAP EPS of DKK16.61.Revenue of DKK1.58B (+77.1% Y/Y)Press Release For further details see: Genmab A/S reports Q1 results
Genmab (GMAB) reports worldwide Darzalex (daratumumab) net sales of $1,365M in Q1 2021.U.S. sales were $691M.Genmab receives royalties on the worldwide net sales of Darzalex under the exclusive license agreement with Janssen Biotech, to develop, manufacture and commercialize daratumumab....
Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%. For further details see: KPTI, CENX, GMAB and TCRR among after-hours movers
FDA action date is Oct 10, 2021 BLA submission supported by positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced ...
The fund just received a huge distribution boost, making it more appealing to income-oriented investors. The latest declines in BMEZ also coincide with an attractive discount on the fund. BMEZ is an attractive long-term option in the healthcare space that focuses on new tech - tho...
Genmab (GMAB) announces that the European Commission ((EC)) has granted Novartis (NVS) marketing authorization for the use of Kesimpta (ofatumumab) in the treatment of relapsing forms of multiple sclerosis ((RMS)) in adults. The approval was based on data from the Phase 3 ASCLEPIOS I and...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...